When we're researching a company, it's sometimes hard to find the warning signs, but there are some financial metrics that can help spot trouble early. When we see a declining return on capital employed (ROCE) in conjunction with a declining base of capital employed, that's often how a mature business shows signs of aging. Ultimately this means that the company is earning less per dollar invested and on top of that, it's shrinking its base of capital employed. So after glancing at the trends within Bolak (KRX:002760), we weren't too hopeful.
Return On Capital Employed (ROCE): What is it?
For those who don't know, ROCE is a measure of a company's yearly pre-tax profit (its return), relative to the capital employed in the business. To calculate this metric for Bolak, this is the formula:
Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)
0.0029 = ₩144m ÷ (₩54b - ₩4.2b) (Based on the trailing twelve months to December 2020).
Therefore, Bolak has an ROCE of 0.3%. In absolute terms, that's a low return and it also under-performs the Chemicals industry average of 7.9%.
View our latest analysis for Bolak
Historical performance is a great place to start when researching a stock so above you can see the gauge for Bolak's ROCE against it's prior returns. If you're interested in investigating Bolak's past further, check out this free graph of past earnings, revenue and cash flow.
So How Is Bolak's ROCE Trending?
In terms of Bolak's historical ROCE movements, the trend doesn't inspire confidence. About five years ago, returns on capital were 2.9%, however they're now substantially lower than that as we saw above. Meanwhile, capital employed in the business has stayed roughly the flat over the period. Since returns are falling and the business has the same amount of assets employed, this can suggest it's a mature business that hasn't had much growth in the last five years. If these trends continue, we wouldn't expect Bolak to turn into a multi-bagger.
What We Can Learn From Bolak's ROCE
All in all, the lower returns from the same amount of capital employed aren't exactly signs of a compounding machine. The market must be rosy on the stock's future because even though the underlying trends aren't too encouraging, the stock has soared 163%. In any case, the current underlying trends don't bode well for long term performance so unless they reverse, we'd start looking elsewhere.
Bolak does have some risks though, and we've spotted 1 warning sign for Bolak that you might be interested in.
If you want to search for solid companies with great earnings, check out this free list of companies with good balance sheets and impressive returns on equity.
When trading Bolak or any other investment, use the platform considered by many to be the Professional's Gateway to the Worlds Market, Interactive Brokers. You get the lowest-cost* trading on stocks, options, futures, forex, bonds and funds worldwide from a single integrated account. Promoted
Valuation is complex, but we're here to simplify it.
Discover if Bolak might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisThis article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
About KOSE:A002760
Bolak
Engages in the manufacture and sale of food ingredients, pharmaceutical raw materials, functional materials, and cosmetic ingredients in South Korea and internationally.
Flawless balance sheet with solid track record.